HC Wainwright Has Bullish Forecast for MeiraGTx Q2 Earnings

MeiraGTx Holdings PLC (NASDAQ:MGTX) – Research analysts at HC Wainwright increased their Q2 2026 earnings estimates for shares of MeiraGTx in a report released on Tuesday, May 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.50) for the quarter, up from their previous forecast of ($0.60). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for MeiraGTx’s Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.98) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.52) EPS and FY2027 earnings at $0.67 EPS.

MeiraGTx (NASDAQ:MGTX) last released its earnings results on Thursday, May 14th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.04. The firm had revenue of $0.29 million for the quarter, compared to analyst estimates of $17.00 million. MeiraGTx had a negative net margin of 151.12% and a negative return on equity of 1,065.47%.

Other equities research analysts have also issued reports about the stock. Zacks Research raised shares of MeiraGTx from a “strong sell” rating to a “hold” rating in a report on Monday, March 9th. Bank of America lifted their price target on shares of MeiraGTx from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 27th. Piper Sandler lifted their price target on shares of MeiraGTx from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, April 22nd. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of MeiraGTx in a report on Friday, March 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MeiraGTx in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, MeiraGTx has a consensus rating of “Moderate Buy” and an average target price of $25.83.

MeiraGTx Trading Up 3.0%

Shares of MeiraGTx stock opened at $9.89 on Thursday. The firm has a market capitalization of $915.91 million, a PE ratio of -6.68 and a beta of 1.23. The firm’s 50 day moving average is $9.19 and its 200 day moving average is $8.31. MeiraGTx has a 1 year low of $5.02 and a 1 year high of $11.85.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its position in shares of MeiraGTx by 43.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock worth $31,000 after purchasing an additional 1,466 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of MeiraGTx by 390.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock worth $57,000 after purchasing an additional 7,005 shares during the period. ProShare Advisors LLC acquired a new position in shares of MeiraGTx in the 4th quarter worth approximately $94,000. Bank of Nova Scotia acquired a new position in shares of MeiraGTx in the 1st quarter worth approximately $105,000. Finally, Abel Hall LLC acquired a new position in shares of MeiraGTx in the 4th quarter worth approximately $98,000. Institutional investors and hedge funds own 67.48% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Richard Giroux sold 56,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $10.22, for a total value of $572,320.00. Following the transaction, the chief financial officer owned 971,530 shares in the company, valued at approximately $9,929,036.60. The trade was a 5.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alexandria Forbes sold 62,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.17, for a total transaction of $568,540.00. Following the completion of the transaction, the chief executive officer owned 1,387,695 shares in the company, valued at $12,725,163.15. This trade represents a 4.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 207,661 shares of company stock valued at $1,859,187 in the last ninety days. 7.50% of the stock is currently owned by insiders.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.